[The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin].
Kept under medical surveillance were 120 patients with duodenal ulcer running an uncomplicated course. All patients and 30 healthy donors were studied for the status of the immunity T-system by spontaneous E-rosette formation (E-RFC) and availability of theophylline-resistant (TPP-RFC) and theophylline-sensitive (TPS-RFC) lymphocytes. With B-system being studied by FAC-rosette formation. All patients with duodenal ulcer displayed a decline in the content of E-RFC, TFP-RFC, TFS-RFC as compared to the indices in controls. Inclusion into the combined therapy of thymalin and dalargin was noted to be associated with a positive dynamics in the rise of T-lymphocytes, their subpopulations to the level in controls, percentage of TFS-RFC. Indices for TFS-RFC did not differ from control ones either before or after the treatment.
Lukash
N V
NV
Polishchuk
T F
TF
Ludan
V V
VV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D016175:B-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D002908:Chronic Disease; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000276:immunology*; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013951:Thymus Hormones; D016308:Enkephalin, Leucine-2-Alanine; C032805:thymalin; C040996:enkephalin-Leu, Ala(2)-Arg(6)-